Analysis of the disease burden of prostate cancer and early prevention and control strategies

doi:10.3877/cma.j.issn.1674-3253.2026.03.003

Abstract

Abstract:

Prostate cancer poses a major threat to the health of men globally and in China, with its disease burden continuing to increase, accompanied by significant disparities across regions, between urban and rural areas, and among different age groups. This article reviews the global and Chinese epidemiological status of prostate cancer, as well as its incidence and mortality trends, analyzes the core characteristics of the disease burden, and systematically elaborates on international and domestic early prevention and control strategies. It also identifies the challenges currently faced in prevention and treatment, and finally puts forward targeted suggestions. The aim is to provide references for promoting precise prevention and control of prostate cancer and reducing the harm caused by the disease.

Key words: Prostate cancer, Disease burden, Early screening, Prevention and control strategies

Lili Chen, Yuxin Zeng, Jun Li. Analysis of the disease burden of prostate cancer and early prevention and control strategies[J]. Chinese Journal of Endourology(Electronic Edition), 2026, 20(03): 255-260.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2026.03.003

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2026/V20/I03/255

References 40

[1]	Collaborators G2C. The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023[J]. Lancet, 2025, 406(10512): 1565-1586. DOI: 10.1016/S0140-6736(25)01635-6.
[2]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[3]	He Y, Xu W, Xiao YT, et al. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials[J]. Sig Transduct Target Ther, 2022, 7(1): 198. DOI: 10.1038/s41392-022-01042-7.
[4]	Chen S, Cao Z, Prettner K, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050[J]. JAMA Oncol, 2023, 9(4): 465-472. DOI: 10.1001/jamaoncol.2022.7826.
[5]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[6]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[7]	瞿旻, 高旭. 2022年全球及中国前列腺癌流行状况分析[J]. 海军军医大学学报, 2025, 46(2): 229-233. DOI: 10.16781/j.CN31-2187/R.20240685.
[8]	Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location[J]. Am J Mens Health, 2018, 12(6): 1807-1823. DOI: 10.1177/1557988318798279.
[9]	Majdalany SE, Butaney M, Tinsley S, et al. Challenges of urologic oncology in low-to-middle-income countries[J]. Société Int D'urologie J, 2024, 5(5): 303-311. DOI: 10.3390/siuj5050049.
[10]	Marima R, Mbeje M, Hull R, et al. Prostate cancer disparities and management in southern Africa: insights into practices, norms and values[J]. Cancer Manag Res, 2022, 14: 3567-3579. DOI: 10.2147/CMAR.S382903.
[11]	Shete K, Ghoulian J, Hu B, et al. Genitourinary cancer care in low- and middle-income countries: disparities in incidence and access to care[J]. Société Int D’urologie J, 2024, 5(5): 330-338. DOI: 10.3390/siuj5050052.
[12]	Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. DOI: 10.1016/j.jncc.2024.01.006.
[13]	闵淑慧, 胡依, 郭芮绮, 等. 1990—2019年中国前列腺癌疾病负担分析及趋势预测[J]. 中国肿瘤, 2023, 32(3): 171-177. DOI: 10.11735/j.issn.1004-0242.2023.03.A002.
[14]	刘哲，杨琳，胡雪华，等. 2011-2020年中国前列腺癌死亡趋势分析及2021-2030年变化趋势预测[J]. 中国肿瘤, 2025, 34(3): 171-177. DOI: 10.11735/j.issn.1004-0242.2025.03.A002
[15]	中华人民共和国国家卫生健康委员会. 2024年我国卫生健康事业发展统计公报[EB/OL]. [2025-12-02]. URL
[16]	赫捷. 2021中国肿瘤登记年报[M]. 北京: 人民卫生出版社, 2023.
[17]	潘剑, 朱耀, 戴波, 等. 2022年度前列腺癌基础研究及临床诊疗新进展[J]. 中国癌症杂志, 2023, 33(3): 210-217. DOI: 10.19401/j.cnki.1007-3639.2023.03.003.
[18]	Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567. DOI: 10.1016/S2214-109X(18)30127-X.
[19]	Zeng H, Zheng R, Sun K, et al. Cancer survival statistics in China 2019-2021: a multicenter, population-based study[J]. J Natl Cancer Cent, 2024, 4(3): 203-213. DOI: 10.1016/j.jncc.2024.06.005.
[20]	Li H, Wang Y, Gong W, et al. Cancer survival analysis on population-based cancer registry data in Zhejiang Province, China (2018-2019)[J]. J Natl Cancer Cent, 2024, 4(1): 54-62. DOI: 10.1016/j.jncc.2023.12.003.
[21]	Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49. DOI: 10.3322/caac.21820.
[22]	Wild CP, Weiderpass E,Stewart BW. World Cancer Report: Cancer research for cancer prevention[M]. Lyon: International Agency for Research on Cancer, 2020.
[23]	Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates[J]. Eur Urol, 2012, 61(6): 1079-1092. DOI: 10.1016/j.eururo.2012.02.054.
[24]	Dave P, Carlsson SV, Watts K. Randomized trials of PSA screening[J]. Urol Oncol, 2025, 43(1): 23-28. DOI: 10.1016/j.urolonc.2024.05.014.
[25]	Tesfai A, Norori N, Harding TA, et al. Variation in harms and benefits of prostate-specific antigen screening for prostate cancer by socio-clinical risk factors: a rapid review[J]. BJUI Compass, 2024, 5(5): 417-432. DOI: 10.1002/bco2.326.
[26]	Kilpeläinen TP, Tammela TL, Roobol M, et al. False-positive screening results in the European randomized study of screening for prostate cancer[J]. Eur J Cancer, 2011, 47(18): 2698-2705. DOI: 10.1016/j.ejca.2011.06.055.
[27]	US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for prostate cancer: us preventive services task force recommendation statement[J]. JAMA, 2018, 319(18): 1901-1913. DOI: 10.1001/jama.2018.3710.
[28]	Osses DF, Remmers S, Schröder FH, et al. Results of prostate cancer screening in a unique cohort at 19yr of follow-up[J]. Eur Urol, 2019, 75(3): 374-377. DOI: 10.1016/j.eururo.2018.10.053.
[29]	Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part I: prostate cancer screening[J]. J Urol, 2023, 210(1): 46-53. DOI: 10.1097/JU.0000000000003491.
[30]	程勇兵, 邱雪峰, 郭宏骞. 2025版EAU前列腺癌指南更新解读[J]. 中国肿瘤外科杂志, 2025, 17(3): 216-220. DOI: 10.3969/j.issn.1674-4136.2025.03.002.
[31]	董志伟. 中国癌症研究进展-第7卷-中国主要癌症的筛查及早诊早治[M]. 北京: 北京大学医学出版社, 2004.
[32]	中国抗癌协会泌尿男生殖系统肿瘤专业委员会前列腺癌学组. 前列腺癌筛查中国专家共识(2021年版)[J]. 中国癌症杂志, 2021, 31(5): 435-440. DOI: 10.19401/j.cnki.1007-3639.2021.05.010.
[33]	赫捷, 陈万青, 李霓, 等. 中国前列腺癌筛查与早诊早治指南(2022，北京)[J]. 中国肿瘤, 2022, 31(1): 1-30. DOI: 10.11735/j.issn.1004-0242.2022.01.A001.
[34]	Ruan X, Zhang N, Wang D, et al. The impact of prostate-specific antigen screening on prostate cancer incidence and mortality in China: 13-year prospective population-based cohort study[J]. JMIR Public Health Surveill, 2024, 10: e47161. DOI: 10.2196/47161.
[35]	Kemesiene J, Nicolau C, Cholstauskas G, et al. Performance of PCA3 and TMPRSS2: ERG within the prostate cancer prevention trial risk calculator version 2 in a Lithuanian cohort[J]. Res Rep Urol, 2025, 17: 95-103. DOI: 10.2147/RRU.S511523.
[36]	Chiu ST, Cheng YT, Pu YS, et al. Prostate health index density outperforms prostate health index in clinically significant prostate cancer detection[J]. Front Oncol, 2021, 11: 772182. DOI: 10.3389/fonc.2021.772182.
[37]	Salloum O, Taciuc IA, Dick A, et al. Diagnostic yield of fusion-guided and randomized biopsies in prostate cancer: evidence for an integrated approach[J]. Healthcare (Basel), 2025, 13(17): 2214. DOI: 10.3390/healthcare13172214.
[38]	雷必秀, 李卿. 人工智能在前列腺癌中的应用研究进展[J]. 数理医药学杂志, 2024, 37(6): 453-461. DOI: 10.12173/j.issn.1004-4337.202403093.
[39]	Shao L, Liang C, Yan Y, et al. An MRI-pathology foundation model for noninvasive diagnosis and grading of prostate cancer[J]. Nat Cancer, 2025, 6(10): 1621-1637. DOI: 10.1038/s43018-025-01041-x.
[40]	Tao W, Yu X, Shao J, et al. Telemedicine-enhanced lung cancer screening using mobile computed tomography unit with remote artificial intelligence assistance in underserved communities: initial results of a population cohort study in western China[J]. Telemed J E Health, 2024, 30(6): e1695-e1704. DOI: 10.1089/tmj.2023.0648.

Please choose a citation manager

Content to export